Status:
COMPLETED
Tramadol to Reduce Opioid Withdrawal Symptoms
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Conditions:
Opioid-Related Disorders
Eligibility:
All Genders
21-55 years
Phase:
PHASE2
Brief Summary
Individuals with opioid addiction often experience serious withdrawal symptoms that may make relapse unavoidable. Tramadol, a medication that is currently used to treat pain caused by chronic conditio...
Detailed Description
Opioid withdrawal symptoms are a major contributing factor for why opioid treatment programs often fail. Individuals with severe opioid withdrawal symptoms may experience shaking, muscle and bone pain...
Eligibility Criteria
Inclusion
- Meets DSM-IV diagnostic criteria for opioid dependence
- Is in good physical health
- Qualifies for treatment with opioid agonist therapy (e.g., methadone)
- If female, must have a negative pregnancy test prior to study entry
Exclusion
- Evidence of significant medical illness (e.g., insulin dependent diabetes mellitus)
- Evidence of significant psychiatric illness (e.g., schizophrenia)
- Currently seeking treatment for substance abuse
- Pregnant or breastfeeding
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2005
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00142896
Start Date
February 1 2005
End Date
December 1 2005
Last Update
January 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins University (BPRU) Bayview Campus
Baltimore, Maryland, United States, 21224-6823